The National Health Service is seeking feedback on its plans to expand its pioneering subscription-style drug contracts to develop lifesaving antibiotics and tackle the problem of antimicrobial resistance.
The National Health Service in England could double the annual payments it offers companies under its pioneering subscription-style contracts for incentivizing them to develop new antibiotics from £10m ($12.90m) to £20m, where outstanding clinically based criteria are met.
In proposals announced today for a 12-week public consultation, NHS England is also seeking input on which products to prioritize,...
The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.
The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.
Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.
The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.
Nearshoring production and diversifying contract manufacturing networks can help companies stave off cost increases that will be reflected in higher medicine prices.
Eli Lilly and PharmaMar were set to make their case before the European Medicines Agency this week as part of re-examination procedures for their respective drugs Kisunla and Aplidin.
The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.
